Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (24779)	10/4/2007 11:44:56 PM
From: Ian@SI	Respond to of 52153

I looked at them briefly during the past year (Think I posted some stuff on this thread around which there was a bit of discussion.) At that time they did not have a PhIII underway in the US, they didn't have much cash I came to the conclusion that there was likely to be several secondaries and a long time before there was any NDA filed. Their mkt cap is quite small considering the drug's potential if successful, but so far I've taken a pass. It seems to me there are many better opportunities out there. Why take the risk with an undercapitalized, one drug pipeline company? Ian

To: Biomaven who wrote (24779)	10/5/2007 4:40:53 AM
From: Sultan	Respond to of 52153

OK.. Thanks.. I took a small position in them around 2 CAD few weeks back.. Basically on the basis that they had enough funding to take the trials to conclusion in 2008, the stock was trading at the low end of the 52 week range, company was confident enough to buy back some of the shares and finally they had a number of presentations scheduled at various conferences etc.. All of this is admittedly intangible but basically playing the normal hoopla with these small names as they get closer to concluding the trial.. Guess I will have to do some reading on them as we roll into 2008..